159 related articles for article (PubMed ID: 12829710)
1. Previtamin D3 with a trans-fused decalin CD-ring has pronounced genomic activity.
Verlinden L; Verstuyf A; Verboven C; Eelen G; De Ranter C; Gao LJ; Chen YJ; Murad I; Choi M; Yamamoto K; Yamada S; Van Haver D; Vandewalle M; De Clercq PJ; Bouillon R
J Biol Chem; 2003 Sep; 278(37):35476-82. PubMed ID: 12829710
[TBL] [Abstract][Full Text] [Related]
2. Interaction of two novel 14-epivitamin D3 analogs with vitamin D3 receptor-retinoid X receptor heterodimers on vitamin D3 responsive elements.
Verlinden L; Verstuyf A; Quack M; Van Camp M; Van Etten E; De Clercq P; Vandewalle M; Carlberg C; Bouillon R
J Bone Miner Res; 2001 Apr; 16(4):625-38. PubMed ID: 11315990
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D receptors from patients with resistance to 1,25-dihydroxyvitamin D3: point mutations confer reduced transactivation in response to ligand and impaired interaction with the retinoid X receptor heterodimeric partner.
Whitfield GK; Selznick SH; Haussler CA; Hsieh JC; Galligan MA; Jurutka PW; Thompson PD; Lee SM; Zerwekh JE; Haussler MR
Mol Endocrinol; 1996 Dec; 10(12):1617-31. PubMed ID: 8961271
[TBL] [Abstract][Full Text] [Related]
4. Potent vitamin D3 analogs: their abilities to enhance transactivation and to bind to the vitamin D3 response element.
Imai Y; Pike JW; Koeffler HP
Leuk Res; 1995 Mar; 19(3):147-58. PubMed ID: 7700077
[TBL] [Abstract][Full Text] [Related]
5. Singly dehydroxylated A-ring analogues of 19-nor-1alpha,25-dihydroxyvitamin D3 and 19-nor-22-oxa-1alpha,25-dihydroxyvitamin D3: novel vitamin D3 analogues with potent transcriptional activity but extremely low affinity for vitamin D receptor.
Okano T; Nakagawa K; Tsugawa N; Ozono K; Kubodera N; Osawa A; Terada M; Mikami K
Biol Pharm Bull; 1998 Dec; 21(12):1300-5. PubMed ID: 9881643
[TBL] [Abstract][Full Text] [Related]
6. New understanding of the molecular mechanism of receptor-mediated genomic actions of the vitamin D hormone.
Haussler MR; Jurutka PW; Hsieh JC; Thompson PD; Selznick SH; Haussler CA; Whitfield GK
Bone; 1995 Aug; 17(2 Suppl):33S-38S. PubMed ID: 8579895
[TBL] [Abstract][Full Text] [Related]
7. Distinct retinoid X receptor activation function-2 residues mediate transactivation in homodimeric and vitamin D receptor heterodimeric contexts.
Thompson PD; Remus LS; Hsieh JC; Jurutka PW; Whitfield GK; Galligan MA; Encinas Dominguez C; Haussler CA; Haussler MR
J Mol Endocrinol; 2001 Oct; 27(2):211-27. PubMed ID: 11564604
[TBL] [Abstract][Full Text] [Related]
8. 1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts.
Kim S; Shevde NK; Pike JW
J Bone Miner Res; 2005 Feb; 20(2):305-17. PubMed ID: 15647825
[TBL] [Abstract][Full Text] [Related]
9. The unique tryptophan residue of the vitamin D receptor is critical for ligand binding and transcriptional activation.
Solomon C; Macoritto M; Gao XL; White JH; Kremer R
J Bone Miner Res; 2001 Jan; 16(1):39-45. PubMed ID: 11149488
[TBL] [Abstract][Full Text] [Related]
10. Regulation of renal parathyroid hormone receptor expression by 1, 25-dihydroxyvitamin D3 and retinoic acid.
Sneddon WB; Barry EL; Coutermarsh BA; Gesek FA; Liu F; Friedman PA
Cell Physiol Biochem; 1998; 8(5):261-77. PubMed ID: 9792954
[TBL] [Abstract][Full Text] [Related]
11. Analysis of vitamin D analog-induced heterodimerization of vitamin D receptor with retinoid X receptor using the yeast two-hybrid system.
Zhao XY; Eccleshall TR; Krishnan AV; Gross C; Feldman D
Mol Endocrinol; 1997 Mar; 11(3):366-78. PubMed ID: 9058382
[TBL] [Abstract][Full Text] [Related]
12. Biologic activity of dihydroxylated 19-nor-(pre)vitamin D3.
Bouillon R; Sarandeses LA; Allewaert K; Zhao J; Mascareñas JL; Mouriño A; Vrielynck S; de Clercq P; Vandewalle M
J Bone Miner Res; 1993 Aug; 8(8):1009-15. PubMed ID: 8213251
[TBL] [Abstract][Full Text] [Related]
13. Thyroid hormone receptor does not heterodimerize with the vitamin D receptor but represses vitamin D receptor-mediated transactivation.
Raval-Pandya M; Freedman LP; Li H; Christakos S
Mol Endocrinol; 1998 Sep; 12(9):1367-79. PubMed ID: 9731705
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D3-retinoid X receptor dimerization, DNA binding, and transactivation are differentially affected by analogs of 1,25-dihydroxyvitamin D3.
Cheskis B; Lemon BD; Uskokovic M; Lomedico PT; Freedman LP
Mol Endocrinol; 1995 Dec; 9(12):1814-24. PubMed ID: 8614417
[TBL] [Abstract][Full Text] [Related]
15. Evidence for 1,25-dihydroxyvitamin D3-independent transactivation by the vitamin D receptor: uncoupling the receptor and ligand in keratinocytes.
Ellison TI; Eckert RL; MacDonald PN
J Biol Chem; 2007 Apr; 282(15):10953-62. PubMed ID: 17310066
[TBL] [Abstract][Full Text] [Related]
16. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
17. Retinoid X receptor is a nonsilent major contributor to vitamin D receptor-mediated transcriptional activation.
Bettoun DJ; Burris TP; Houck KA; Buck DW; Stayrook KR; Khalifa B; Lu J; Chin WW; Nagpal S
Mol Endocrinol; 2003 Nov; 17(11):2320-8. PubMed ID: 12893883
[TBL] [Abstract][Full Text] [Related]
18. Retinoid X receptor:vitamin D3 receptor heterodimers promote stable preinitiation complex formation and direct 1,25-dihydroxyvitamin D3-dependent cell-free transcription.
Lemon BD; Fondell JD; Freedman LP
Mol Cell Biol; 1997 Apr; 17(4):1923-37. PubMed ID: 9121440
[TBL] [Abstract][Full Text] [Related]
19. Gene regulatory potential of 1alpha,25-dihydroxyvitamin D(3) analogues with two side chains.
Bury Y; Herdick M; Uskokovic MR; Carlberg C
J Cell Biochem Suppl; 2001; Suppl 36():179-90. PubMed ID: 11455583
[TBL] [Abstract][Full Text] [Related]
20. The difference between 14-epi-previtamin D3 and 14-epi-19-norprevitamin D3: their synthesis and binding affinity for human VDR.
Sawada D; Katayama T; Tsukuda Y; Saito N; Saito H; Kakuda S; Takimoto-Kamimura M; Takenouchi K; Kittaka A
Anticancer Res; 2012 Jan; 32(1):319-26. PubMed ID: 22213322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
